| 1 |
35337112 | Investigation of the Antitumor Effects of Tamoxifen and Its Ferrocene-Linked Derivatives on Pancreatic and Breast Cancer Cell Lines. | 2022 Mar 5 |
1 |
| 2 |
35445730 | EGFR inhibition reverses epithelial‑mesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells. | 2022 Jun |
5 |
| 3 |
35559420 | YY1 as a promoter regulating the circ_0001946/miR-671-5p/EGFR axis to promote chemotherapy resistance in breast cancer cells. | 2022 |
1 |
| 4 |
33508166 | Investigating differences between tamoxifen resistant and sensitive breast cancer cells with flow cytometry. | 2021 Feb |
2 |
| 5 |
33691171 | A pan-cancer analysis of the HER family gene and their association with prognosis, tumor microenvironment, and therapeutic targets. | 2021 May 15 |
1 |
| 6 |
34006822 | Sodium/glucose cotransporter 1-dependent metabolic alterations induce tamoxifen resistance in breast cancer by promoting macrophage M2 polarization. | 2021 May 18 |
1 |
| 7 |
34058187 | Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway. | 2021 Aug |
1 |
| 8 |
34407787 | Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells. | 2021 Aug 18 |
2 |
| 9 |
32021441 | ERα36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway. | 2020 |
1 |
| 10 |
33046784 | Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells. | 2020 Oct 12 |
1 |
| 11 |
30189107 | PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study. | 2019 Feb |
1 |
| 12 |
31088266 | Colon Cancer Cell Secretes EGF to Promote M2 Polarization of TAM Through EGFR/PI3K/AKT/mTOR Pathway. | 2019 Jan 1 |
1 |
| 13 |
31670920 | EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer. | 2019 |
2 |
| 14 |
31821370 | Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer. | 2019 |
4 |
| 15 |
28786348 | Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance is Required. | 2018 |
1 |
| 16 |
29028222 | Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer. | 2018 Apr 1 |
2 |
| 17 |
29484139 | S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB. | 2018 Jan 26 |
1 |
| 18 |
29787277 | Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer. | 2018 Jul 2 |
1 |
| 19 |
30050469 | Tamoxifen-Induced Apoptosis of MCF-7 Cells via GPR30/PI3K/MAPKs Interactions: Verification by ODE Modeling and RNA Sequencing. | 2018 |
3 |
| 20 |
30140390 | Correction: S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB. | 2018 Jul 31 |
1 |
| 21 |
27225751 | The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen. | 2017 Aug |
5 |
| 22 |
28100469 | Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial. | 2017 Mar |
1 |
| 23 |
28231748 | Aloe-Emodin Enhances Tamoxifen Cytotoxicity by Suppressing Ras/ERK and PI3K/mTOR in Breast Cancer Cells. | 2017 |
1 |
| 24 |
28955730 | TGF-β Stimulation of EMT Programs Elicits Non-genomic ER-α Activity and Anti-estrogen Resistance in Breast Cancer Cells. | 2017 |
1 |
| 25 |
26581908 | Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells. | 2016 May |
2 |
| 26 |
26803986 | HOX genes: Major actors in resistance to selective endocrine response modifiers. | 2016 Apr |
1 |
| 27 |
26884313 | Roles of the ER-α36-EGFR/HER2 positive regulatory loops in tamoxifen resistance. | 2016 Jul |
5 |
| 28 |
27083550 | Delineating the molecular mechanisms of tamoxifen's oncolytic actions in estrogen receptor-negative cancers. | 2016 Jun 15 |
3 |
| 29 |
27494858 | Dichloroacetate potentiates tamoxifen-induced cell death in breast cancer cells via downregulation of the epidermal growth factor receptor. | 2016 Sep 13 |
4 |
| 30 |
27519631 | Tamoxifen has a proliferative effect in endometrial carcinoma mediated via the GPER/EGFR/ERK/cyclin D1 pathway: A retrospective study and an in vitro study. | 2016 Dec 5 |
1 |
| 31 |
25882671 | Factors Promoting Tamoxifen Resistance in Breast Cancer via Stimulating Breast Cancer Stem Cell Expansion. | 2015 |
1 |
| 32 |
25973295 | Downregulation of ER-α36 expression sensitizes HER2 overexpressing breast cancer cells to tamoxifen. | 2015 |
4 |
| 33 |
26166014 | Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells. | 2015 Sep |
3 |
| 34 |
26238412 | HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen. | 2015 Oct |
1 |
| 35 |
26487496 | Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer. | 2015 Nov |
5 |
| 36 |
26697525 | A pivotal role for HOXB7 protein in endocrine resistant breast cancer. | 2015 |
1 |
| 37 |
24414992 | Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients. | 2014 Jul |
2 |
| 38 |
24481325 | GPER-mediated proliferation and estradiol production in breast cancer-associated fibroblasts. | 2014 Apr |
2 |
| 39 |
24758408 | Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation. | 2014 Apr 23 |
1 |
| 40 |
24916398 | Snail and Slug mediate tamoxifen resistance in breast cancer cells through activation of EGFR-ERK independent of epithelial-mesenchymal transition. | 2014 Aug |
1 |
| 41 |
25203051 | Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells. | 2014 |
6 |
| 42 |
23609470 | Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. | 2013 May |
2 |
| 43 |
24091623 | Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial. | 2013 Oct 29 |
2 |
| 44 |
21690342 | The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. | 2012 Feb 21 |
3 |
| 45 |
21935603 | The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin. | 2012 Jun |
1 |
| 46 |
22808167 | Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer. | 2012 |
1 |
| 47 |
22922893 | Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells. | 2012 Nov |
1 |
| 48 |
23039365 | Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. | 2012 Oct 6 |
1 |
| 49 |
23273253 | Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancer. | 2012 Dec 28 |
2 |
| 50 |
20133149 | Adjuvant endocrine therapy in postmenopausal breast cancer patients: does hormone receptor status influence decision-making? | 2011 Feb |
1 |